|
|
|
 |
 |
|
       |
|
|
|
News | December 10, 2001  Protein Sciences Announces Contract with The National Institute Of Allergy and Infectious Diseases for Production of new HIV/AIDS Vaccines Over $2 Million in Funding Already Approved and up to $76 Million could be Accessed Meriden, CT, December 10, 2001 - Protein Sciences Corporation (PSC) announced today that it has signed a contract with the National Institute of Allergy and Infections Diseases (NIAID) that provides for up to $76 million in funding through mid-2006 for development and production of antigens for new vaccines for HIV/AIDS. Under the contract, after NIAID approves a vaccine candidate it will issue a task order to fund Protein Sciences to develop and manufacture clinical materials suitable for Phase I, II and III human clinical trials. Industry and institutions in the U.S or abroad qualify for funding. Manon Cox, PSC's Vice President, Corporate and Process Development, commented, "Our Company has a long history of involvement in developing HIV/AIDS vaccines, and we have extensive experience in producing clinical materials to support large scale human clinical trials using our proprietary baculovirus expression vector technology. Many companies have been reluctant to develop new vaccines for this dreaded disease because of economic considerations and this contract makes it possible to obtain government funding for a significant part of the development cost." She added, "We already have received task orders for over $2 million in funding for p55 and a synthetic protein being developed by a biotechnology company. The approval process is straightforward and rapid, and we strongly encourage companies and institutions to take advantage of this opportunity." Founded in 1983, Protein Sciences Corporation (www.proteinsciences.com) is the world leader in developing genes coding for proteins into commercial human and veterinary vaccines, therapeutics and diagnostics using its proprietary baculovirus expression vector system (BEVS) technology that includes its patented expresSF+® serum free, high yielding, scalable insect cell line. Customers access PSC's proprietary BEVS technology through its GeneXpress® program. This allows them to obtain cGMP human and animal clinical materials more reliably, rapidly and less expensively than through alternative protein expression systems. |
|
|
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
